RANDON JENKINS: Open Payments
NPI 1093217218 · WARREN, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,069 in 21 payments from 13 companies in 2025. Trend: 2023 $139 · 2024 $444 · 2025 $1,069
Food & beverage: $1,069
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $289 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $180 |
| Astellas Pharma US Inc | 1 | $126 |
| Phathom Pharmaceuticals, Inc. | 1 | $116 |
| Janssen Pharmaceuticals, Inc | 1 | $99 |
| Dexcom, Inc. | 2 | $82 |
| Neurocrine BioSciences, Inc. | 1 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $17 |
Products named: BREZTRI, CAPLYTA, Veozah, VOQUEZNA, INVEGA SUSTENNA, INGREZZA, DEXCOM G7 GSS (161), GVOKE HYPOPEN.
Industry payments across MI — which companies pay providers there.
